GlaxoSmithKline News and Research

RSS

Ranbaxy and GSK agree to settle Valacyclovir U.S. patent case

Ranbaxy Laboratories Limited (RLL) announced today that the Company has reached an agreement with GlaxoSmithKline (GSK) resulting in a dismissal of their U.S. litigation with regard to Valtrex(R) (Valacyclovir Hydrochloride tablets).

27 Jul 2007

Initiative to improve heart failure care at nation's hospitals makes major gains

A national initiative designed to improve heart-failure patient care in hospitals proved effective at increasing hospital adherence to key quality-of-care performance measures and reducing the length of hospital stays for patients.

24 Jul 2007

GSK's Cervarix receives positive opinion in Europe

GlaxoSmithKline has announced that its cervical cancer candidate vaccine received a positive opinion from the European Committee for Human Medicinal Products (CHMP) for the prevention of precancerous lesions (high grade cervical intraepithelial neoplasia - CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus types 16 and 18.

19 Jul 2007

Review of Rosiglitazone for type 2 diabetes mellitus

Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes, according to a systematic review of data by German researchers.

18 Jul 2007

Alli jokes - great marketing!

GlaxoSmithKline's new diet drug, Alli, hit shelves nationwide last month.

4 Jul 2007

Trial shows CERVARIX cervical cancer candidate vaccine effective

Results from an interim analysis of a Phase III study show that CERVARIX, the GlaxoSmithKline (GSK) cervical cancer candidate vaccine, provides up to 100 percent protection against advanced precancerous lesions caused by the most common types of human papillomavirus, types 16 and 18.

28 Jun 2007

Global stockpile of H5N1 vaccines

The World Health Organization (WHO) today announced that it is working with vaccine manufacturers to move ahead on plans to create a global stockpile of vaccine for the H5N1 avian influenza virus.

19 Jun 2007

Alli hits the stores

The first non-prescription diet drug ever to be approved by the FDA hit the shops this week and optimistic dieters are dashing out to buy it.

19 Jun 2007

OTC diet pill Alli now on sale in the U.S.

The first and only over-the-counter (OTC) product for weight loss approved by the Food and Drug Administration (FDA) has gone on sale in the U.S.

18 Jun 2007

Drug giant donates bird flu vaccine to WHO stockpile

Europe's largest drugmaker GlaxoSmithKline (GSK) has promised to donate 50 million doses of its "pre-pandemic" bird flu vaccine for humans to a global stockpile for distribution in the world's poorest countries.

14 Jun 2007

Priority review granted for oral formulation of HYCAMTIN (topotecan)

GlaxoSmithKline (GSK) has announced that its new drug application (NDA) for ORAL HYCAMTIN (topotecan) capsules, a treatment for relapsed small cell lung cancer (SCLC), has been granted Priority Review by the United States Food and Drug Administration (FDA).

14 Jun 2007

Alli weight loss drug on the U.S. market soon

Alli which is produced by GlaxoSmithKline will be available to consumers in America next week following a 150 million dollar advertising campaign to promote the non-prescription drug.

12 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

Drug lapatinib shows activity against brain metastases

The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2007

More considered approach to the safety of rosiglitazone needed

A calmer and more considered approach to the safety of rosiglitazone (Avandia) - the GlaxoSmithKline treatment for type 2 diabetes - is needed to avoid unnecessary panic among patients, says an Editorial published online and in an upcoming edition of The Lancet.

28 May 2007

Tracing the path of depression

David Nutt, Professor of Psychopharmacology, said: "The development of one of these radioactive tracers to enable the study of noradrenaline and its related processes in those suffering depression is critical to our proper understanding of this disease.

27 May 2007